Meet the patients that are eligible to receive SHINGRIX
Nearly everyone ≥50 years old should be protected against shingles.3
EN
English
Anoro Ellipta 20 mcg
Added to your cart
59
By helping prevent shingles, SHINGRIX significantly decreased the incidence of PHN in patients aged ≥70 overall1*
Adapted from SHINGRIX Product Monograph.
8,250 PATIENTS ≥70 YEARS OF AGE RECEIVED SHINGRIX.1
FOUR CASES OF PHN WERE REPORTED IN THIS AGE GROUP.1
The benefit of SHINGRIX on PHN can be attributed to the effect of the vaccine on the prevention of HZ. A further reduction of PHN incidence in subjects with confirmed HZ could not be demonstrated due to the limited number of HZ cases in the vaccine group.¹
SHINGRIX is not indicated for the treatment of HZ or PHN.1
* PHN was defined as shingles-associated pain rated as ≥3 on a 0–10 scale, occurring or persisting for at least 90 days following the onset of rash using the Zoster Brief Pain Inventory questionnaire.1,2
Based on pooled data from ZOE-50 and ZOE-70.
Cumulative incidence of herpes zoster over time in adults aged ≥50 in the ZOE-50 study (mTVC)1
In the fourth year after vaccination, vaccine efficacy (VE) against shingles in patients ≥50 years in ZOE-50 was 93.1% vs. placebo (95% CI: 81.2, 98.2).1
Adapted from SHINGRIX Product Monograph.
Cumulative incidence of herpes zoster over time in adults aged ≥70 in the pre-specified pooled ZOE-50/ZOE-70 analysis (mTVC)1
In the fourth year after vaccination, VE against shingles in patients ≥70 years was 87.9% vs. placebo (95% CI: 73.3, 95.4).1
Adapted from SHINGRIX Product Monograph.
References:
Trademarks are owned by or licensed to the GSK group of companies.
©2022 GSK Group of Companies or its licensor.
10141 | 12/22